Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Expects Q3 Revenues In Line with Expectations

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market yesterday that it expects its third-quarter revenues to be roughly $41 million, in line with analysts' consensus estimate of $40.8 million.

The Sunnyvale, Calif.-based firm will report its third-quarter results on Oct. 28, after the close of the market.

Cepheid disclosed its Q3 revenue expectation in a statement announcing that it had hired Nicolaas Arnold to serve as executive vice president of worldwide commercial operations, effective today. Arnold joins Cepheid from Siemens, where he was regional VP for Siemens Healthcare Diagnostics in Northwest Europe with responsibility for molecular diagnostics, central lab, and point-of-care sales.

"We are looking to grow both our domestic and international markets, and this is a timely appointment that further strengthens our sales and marketing capabilities with the objective of establishing the GeneXpert System as the molecular platform of choice," Cepheid CEO John Bishop said in a statement.

Cepheid's shares were up nearly 6 percent at $13.90 in early Wednesday trade on the Nasdaq.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.